{"entity":{"id":"nct05806385","kind":"trial","name":"Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers","aka":["LOGIC"],"tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Texas Tech University Health Sciences Center, not yet recruiting.","summary":"Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers is a phase 1/2, randomised interventional study registered as NCT05806385 by Texas Tech University Health Sciences Center, with a registry enrolment figure of 36 participants, started 2026-03 and due to reach its primary completion in 2027-01. Interventions recorded: Cryoablation; Cryoablation combined with PD1 Inhibitor. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* Diagnoses: Invasive carcinoma, ER -, PR-, HER2- (triple negative)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05806385","url":"https://clinicaltrials.gov/study/NCT05806385"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05806385","phase":"1/2","setting":"Local Therapy Optimization by Grouping Immune-modulation With Cryoablation (LOGIC) for High Risk Breast Cancers","sponsor":"Texas Tech University Health Sciences Center","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05806385/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}